TPD Assay Development & Screening Summit

Uniting Technical Personnel to Expand Assay Capabilities for Next Generation Protein Degraders
Bringing together technical expertise sharing case studies with actionable insights, the Inaugural TPD Assay Development & Screening Summit has been established as the first and only industry dedicated conference to support in-house assay development and screening strategies to find new targets, uncover novel ligands, drive down costs and progress from early discovery to drug candidate with scalable compounds.

With new technologies such as CryoEM and DNA encoded libraries showing promise, join us as we take a deep dive into the key challenges holding back the progression of candidates into pre-clinical studies by determining the best technologies and methodologies for your programs.

Prices:
Drug Developer Pricing - Conference + 2 Workshops - On the Door USD 4297.00
Drug Developer Pricing - Conference + 1 Workshop - On the Door USD 3648.00
Drug Developer Pricing - Conference Only - On the Door USD 2999.00
Academic Pricing - Conference + 2 Workshops - On the Door USD 3697.00
Academic Pricing - Conference + 1 Workshop - On the Door USD 3148.00
Academic Pricing - Conference Only - On the Door USD 2599.00
Service Provider Pricing - Conference + 2 Workshops - On the Door USD 5097.00
Service Provider Pricing - Conference + 1 Workshop - On the Door USD 4348.00
Service Provider Pricing - Conference Only - On the Door USD 3599.00

Speakers: Jerry Crabtree, David Korn Professor, Stanford University Medical School, Joel Austin, Senior VP of Platform Technology Development, Seed Therapeutics, Anastasia Velentza, Senior Director Head of Discovery Technology, Plexium, Dongwen Lyu (Lv), Assistant Professor/ Research, Department of Biochemistry & Structural Biology at UT Health San Antonio, Miguel Coelho, Associate Director, PhoreMost Ltd, Breanna Zerfas, Scientist, Dana-Farber Cancer Institute, Matthew Oser, Assistant Professor of Medicine, Harvard Medical School, Vidyasagar Koduri, Oncologist, Dana-Farber Cancer Institute, Ricardo Medina, Senior Scientist New Targets Biology, Foghorn Therapeutics, Toren Finkel, Professor & Director of the Aging Institute, University of Pittsburgh School of Medicine, Kirti Sharma, Director - Proteomics, Kymera Therapeutics, Taosheng Chen, Full Member (Professor) Director of High Throughput Bioscience Center, St. Jude Children’s Research Hospital, Vladimiras Oleinikovas, Senior Scientist & Computational Chemist, Monte Rosa Therapeutics, Ilaria Lamberto, Senior Scientist, Monte Rosa Therapeutics, Ralph Mazitschek, Assistant Professor, Massachusetts General Hospital/ Harvard Medical School, Harris Bell-Temin Associate Director, Discovery Proteomic Platforms, Janssen Pharmaceutical Companies of Johnson & Johnson, Helen Harrison, Director - Screening, Amphista Therapeutics, Dirksen Bussiere, Associate Vice- President, Molecular Pharmacology, Eli Lilly

Others Details

Brochure https://go.evvnt.com/1263588-3?pid=6581